Dr. Bogdana Schmidt

Hello, everyone, and welcome back to the Backtable podcast, your source for all things urology. You can find all previous episodes of our podcast on Apple Podcasts, Spotify, and at backtable.com. My name is Bogdana Schmidt, and it is my pleasure to introduce Dr. Andrea Apollo.

Hello, everyone, and welcome back to the Backtable podcast, your source for all things urology. You can find all previous episodes of our podcast on Apple Podcasts, Spotify, and at backtable.com. My name is Bogdana Schmidt, and it is my pleasure to introduce Dr. Andrea Apollo.

Hello, everyone, and welcome back to the Backtable podcast, your source for all things urology. You can find all previous episodes of our podcast on Apple Podcasts, Spotify, and at backtable.com. My name is Bogdana Schmidt, and it is my pleasure to introduce Dr. Andrea Apollo.

She's a tenured senior investigator, medical oncologist, and acting deputy chief of the Geomalignancies Branch and head of the Bladder Cancer Center at the NIH. She's led numerous GU clinical trials, including one we'll be discussing today. Dr. Apollo, welcome to the Backtable podcast. Thank you so much for having me. I really appreciate it. I'm really looking forward to this conversation.

She's a tenured senior investigator, medical oncologist, and acting deputy chief of the Geomalignancies Branch and head of the Bladder Cancer Center at the NIH. She's led numerous GU clinical trials, including one we'll be discussing today. Dr. Apollo, welcome to the Backtable podcast. Thank you so much for having me. I really appreciate it. I'm really looking forward to this conversation.

She's a tenured senior investigator, medical oncologist, and acting deputy chief of the Geomalignancies Branch and head of the Bladder Cancer Center at the NIH. She's led numerous GU clinical trials, including one we'll be discussing today. Dr. Apollo, welcome to the Backtable podcast. Thank you so much for having me. I really appreciate it. I'm really looking forward to this conversation.

We'll be discussing highlights specifically in the bladder cancer field presented at ESMO 2024 in beautiful Barcelona. Before we get into it, I just want to point out how alive our field is right now. The meeting had over 5,000 abstracts submitted, over 600 invited speakers, but what I found fascinating was the statistics on the number of trials going on in GU right now.

We'll be discussing highlights specifically in the bladder cancer field presented at ESMO 2024 in beautiful Barcelona. Before we get into it, I just want to point out how alive our field is right now. The meeting had over 5,000 abstracts submitted, over 600 invited speakers, but what I found fascinating was the statistics on the number of trials going on in GU right now.

We'll be discussing highlights specifically in the bladder cancer field presented at ESMO 2024 in beautiful Barcelona. Before we get into it, I just want to point out how alive our field is right now. The meeting had over 5,000 abstracts submitted, over 600 invited speakers, but what I found fascinating was the statistics on the number of trials going on in GU right now.

In my very young urologic oncology life, this is still incredibly impressive. There are currently 351 active trials in RCC, 188 in prostate cancer, and 929 in bladder cancer. This is unbelievable.

In my very young urologic oncology life, this is still incredibly impressive. There are currently 351 active trials in RCC, 188 in prostate cancer, and 929 in bladder cancer. This is unbelievable.

In my very young urologic oncology life, this is still incredibly impressive. There are currently 351 active trials in RCC, 188 in prostate cancer, and 929 in bladder cancer. This is unbelievable.

Absolutely. And I think that goal actually is reachable. You know, when I started even just a few years ago, I used to tell patients, look, if we're still doing the same thing in bladder cancer 10 years from now, we haven't done our jobs. And even in the last few years, we've made such interesting and promising advances that I'm really hopeful we'll get there.

Absolutely. And I think that goal actually is reachable. You know, when I started even just a few years ago, I used to tell patients, look, if we're still doing the same thing in bladder cancer 10 years from now, we haven't done our jobs. And even in the last few years, we've made such interesting and promising advances that I'm really hopeful we'll get there.

Absolutely. And I think that goal actually is reachable. You know, when I started even just a few years ago, I used to tell patients, look, if we're still doing the same thing in bladder cancer 10 years from now, we haven't done our jobs. And even in the last few years, we've made such interesting and promising advances that I'm really hopeful we'll get there.

So I wasn't sure the best way to organize this chat. So I think maybe we should start with the most advanced, most likely to be practice changing abstract, and then spend some time on things that are interesting and thought provoking, maybe not quite prime time.

So I wasn't sure the best way to organize this chat. So I think maybe we should start with the most advanced, most likely to be practice changing abstract, and then spend some time on things that are interesting and thought provoking, maybe not quite prime time.

So I wasn't sure the best way to organize this chat. So I think maybe we should start with the most advanced, most likely to be practice changing abstract, and then spend some time on things that are interesting and thought provoking, maybe not quite prime time.

But I definitely want to get your thoughts on where you think the field is heading and what you'll be looking forward to in future meetings. So with that in mind, let's jump into the Niagara trial presented to Dr. Tom Powell's.

But I definitely want to get your thoughts on where you think the field is heading and what you'll be looking forward to in future meetings. So with that in mind, let's jump into the Niagara trial presented to Dr. Tom Powell's.